Zacks Investment ResearchMon, 20 Apr 2026 16:46:29 GMTKROS 2026 Watchlist: 3 Catalysts That Could Reset SentimentKROS+3.69%
Zacks Investment ResearchMon, 20 Apr 2026 16:41:33 GMTKROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?KROS+3.69%
Zacks Investment ResearchMon, 20 Apr 2026 16:30:29 GMTKROS Rinvatercept: What to Know Before DMD Phase II StartsKROS+3.69%
Zacks Investment ResearchFri, 03 Apr 2026 16:31:16 GMTWhy Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?KROS+3.69%
Zacks Investment ResearchTue, 17 Mar 2026 18:20:24 GMTKROS Stock: What to Know About Rinvatercept in DMDKROS+3.69%
Zacks Investment ResearchTue, 17 Mar 2026 18:20:23 GMTKROS: Is the Discount Book Value a Value Trap?KROS+3.69%
Zacks Investment ResearchTue, 17 Mar 2026 18:20:21 GMTKROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026KROS+3.69%
Zacks Investment ResearchFri, 06 Mar 2026 18:01:36 GMTCan Keros Therapeutics Rinvatercept Stand Out in the DMD Market?KROS+3.69%
Zacks Investment ResearchWed, 04 Mar 2026 23:10:11 GMTKeros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue EstimatesKROS+3.69%
Zacks Investment ResearchWed, 18 Feb 2026 15:42:09 GMTShould Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?KROS+3.69%
